Economic issues in postexposure rabies treatment

Journal of Travel Medicine

Volumn 6, Issue 4, 1999, Pages 238-242

  Wilde, Henry ^a,b   Tipkong, Penmas ^a   Khawplod, Pakamatz ^a  

^a KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^b QUEEN SAOVABHA MEMORIAL INSTITUTE   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

RABIES VACCINE;

DOG; DRUG COST; HEALTH ECONOMICS; HUMAN; INFECTION CONTROL; NONHUMAN; RABIES; REVIEW; VACCINATION; VIRUS INFECTION; WORLD HEALTH ORGANIZATION;

EID: 0345440105     PISSN: 11951982     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1708-8305.1999.tb00525.x     Document Type: Review

References (30)

1. Seghal S, Bhatacharya D, Bhardwaj M. Clinical evaluation of purified vero cell rabies vaccine in patients bitten by rabid animals in India.J Comm Dis 1994; 26:139-146.
2. Kositprapa C, Wimalaratna O, Chomchey P, et al. Problems with rabies postexposure management; a survey of 499 public hospitals in Thailand.J Travel Med 1998; 5:30-32.
3. Wilde H. Rabies, 1996. Internat J Infect Dis 1997; 1:135-142.
4. Parviz S, Luby S, Wilde H. Postexposure treatment of rabies in Pakistan. Clin Infect Dis 1998; 27:751-756.
5. Ogunkoya AB, Macconi F. Emergence of antirabies vaccine of unknkown origin in Nigeria. Vaccine 1986; 4:77-78.
6. Mitmoonpitak C, Tepsumethanon V, Wilde H. Rabies in Thailand (veterinary aspects). Epidemiol Infect 1998; 120:165-169.
7. World Health Organization, Expect Committee on Rabies. Report. Geneva: WHO 1992.
8. World Health Organization. Report of a consultation on intradermal application of human rabies vaccines. WHO, Geneva 1995;WHO/RAB. Res. 95.47.
9. Chutivongse S, Wilde H, Fishbein DB, et al. One year study of the 2-1-1 intramuscular postexposure rabies vaccine regimen in 100 severely exposed Thai patients using rabies immune globulin and vero cell rabies vaccine. Vaccine 1991; 9:573-576.
10. Vodopija I, Sureau P, Smerdel S, et al. Comparative study of two human diploid cell rabies vaccines administered with antirabies globulin. Vaccine 1998; 6:489-490.
11. Pairoj V. Humoral and cell mediated immune response to a new abbreviated regimen of purified vero cell rabies vaccine. Master of Science Thesis, Graduate School, Chulalongkorn University, Bangkok, Thailand 1998(ISBN 974-569-393-6).
12. Lang J, Soerjosembodo S, Simanjuntak G, et al. Suppressant effect of human or equine rabies immunoglobulin on the immunogenicity of postexposure rabies vaccination under the 2-1-1 regimen: a field trial in Indonesia. WHO Bull 1998; 76:491-495.
13. Phanuphak P, Khawplod P, Sirivchayakul S, et al. Humoral and cell-mediated immune response to various economical regimens of purified vero cell rabies vaccine. Asia Pac J Allergy Immunol 1987; 5:33-37.
14. Warrell MJ, Nicholson KG, Warrell DA, et al. Economical multiple site intradermal immunization with human diploid-cell strain vaccine is effective for postexposure rabies prophylaxis. Lancet 1985; 1:1059-1062.
15. Chantanakajorntung A, Naraporn N, Khumpkhai W, et al. A post mortality review of human rabies immune globulin manufactured by the Thai Red Cross Society. Vaccine 1998, in press.
16. Wilde H, Chutivongse S. Equine rabies immune globulin: a product with an undeserved poor reputation. Am J Trop Med Hyg 1990; 42:175-178.
17. Tantawichien T, Benjavongkulchai M, Wilde H, et al. Value of skin test for predicting reaction to equine rabies immune globulin. Clin Infect Dis 1995, 21:660-662.
18. Wilde H, Tipkong P, Sitprija V, Chaiyabutr N. Heterologous antisera and antivenins are essential biologicals; perspectives of a worldwide crisis. Ann Intern Med 1996; 125:233-236.
19. World Health Organization. World survey of rabies No. 31. 1997; WHO Geneva, document WHO/EMZOO/97.1.
20. Wilde H, Sirikawin S, Sabcharoen A, et al. Failure of postexposure treatment of rabies in children. Clin Infect Dis 1996; 22:228-232.
21. Wilde H. Preexposure rabies vaccination.J Travel Med 1994; 1:51-54.
22. Bernard KW, Fishbein DB, Miller KD, et al. Preexposure rabies immunization with human diploid cell vaccine: decreased antibody responses in persons immunized in developing countries. Am J Trop Med Hyg 1985; 34(3):633-645.
23. Biggs DJ, Schwenke RJ. Longevity of rabies antibody titer in recipients of human diploid cell rabies vaccine. Vaccine 1992; 10:125-128.
24. Kositprapa C, Limsuwun K, Wilde H, et al. Immune response to stimulated postexposure rabies booster vaccination. Clin Infect Dis 1997; 25:614-616.
25. Jaijaroensup W, Limusanno S, Khawplod P, et al. Reliability of rabies postexposure booster injections in subjects who had previously received intradermal preexposure vaccination.J Travel Med 1999, in press.
26. Narapong N, Khawplod P, Limsuwan K et al. Immune response to rabies booster vaccination in subjects who had postexposure treatment more than five years previously.J Travel Med 1998, in press.
27. Wilde H, Chutivongse S, Tepsumethanon W, et al. Rabies in Thailand: 1990. Rev Infect Dis 1990; 13:644-652.
28. Matter HC, Schumacher CL, Kharmachit H, et al. Field evaluation of two bait delivery systems for oral immunization of dogs against rabies in Tunesia. Vaccine 1998; 16:657-665.
29. Soon TY. Rabies in Malaysia. Southeast Asian J Trop Med Public Health 1988; 19:535-536.
30. Cleaveland S. The growing problem of rabies in Africa. Trans R Soc Trop Med Hyg 1998; 92:131-134.